Related Experiment Video
Updated: Jul 8, 2026

Epithelial Cell Infection Analyses with Shigella
Published on: February 9, 2024
Death from multi-resistant shigelloses: a case study from Fiji
1Fiji Scool of Medicine, Private Mail Bag, Suva, Fiji. chris_w@fsm.ac.fj
Abstract:
Death from Shigellosis is rare in developed countries, however it causes over a million deaths in developing countries worldwide annually. Death from shigellosis is rare in Fiji. However, the global problem of emerging multi-drug resistance raises some issues about the management of Shigellosis in this country. Within Fiji, Shigella is a notifiable disease. The Fiji Ministry of Health recorded 68 cases of Shigella in 1996, 173 cases in 1997 and 334 cases in 1998 (no data available for 1999). There was only one recorded death during this time--in 1998. Resistance to chloramphenicol occurred in 82% of cases. Shigella flexneri in Fiji remains sensitive to cephalothin and cefaclor. The current antibiotic guidelines in Fiji, recommend that antibiotics be used only for cases of moderate and severe dysentery. Shigellosis was suspected soon after presentation however the patient was unable to take oral antibiotics and was treated with intravenous antibiotics (chloramphenicol and ampicillin), which were ineffective due to resistance of the organism. The current antibiotic guidelines for severe dysentry recommend chloramphenicol or nalidixic acid--the later not available in Fiji. However the only intravenous drugs that retain their sensitivity to Shigella--ceftriaxone and cephalothin, are expensive ($F 45.00 per vial' of ceftdaxone) and these are only available in large regional hospitals.
Insights
Emerging multi-drug resistance in Shigella poses a challenge for Fiji. Shigella flexneri remains sensitive to specific antibiotics, but treatment options are limited and costly.
Area of Science:
- Infectious Diseases
- Microbiology
- Public Health
Background:
- Shigellosis is a significant cause of mortality in developing nations, though rare in developed countries.
- In Fiji, Shigella is a notifiable disease with increasing case numbers reported between 1996 and 1998.
- Emerging multi-drug resistance (MDR) presents a growing concern for Shigellosis management globally and in Fiji.
Observation:
- A high prevalence of chloramphenicol resistance (82%) was observed in Shigella cases in Fiji.
- Shigella flexneri isolates in Fiji demonstrated sensitivity to cephalothin and cefaclor.
- Intravenous antibiotics (chloramphenicol, ampicillin) were ineffective in a patient due to organism resistance.
Findings:
- Current Fiji antibiotic guidelines recommend use only for moderate to severe dysentery.
- Recommended treatments like chloramphenicol and nalidixic acid show high resistance or unavailability.
- Ceftriaxone and cephalothin are the only effective intravenous options but are expensive and not widely accessible.
Implications:
- The study highlights the urgent need for updated treatment protocols and antibiotic stewardship in Fiji.
- Limited access to effective and affordable intravenous antibiotics complicates the management of severe Shigellosis cases.
- Addressing MDR in Shigella is crucial for preventing severe illness and mortality in Fiji and similar settings.
Related Concept Videos
Cholera
Bacterial Gastroenteritis
Reservoir of Infection
Investigation of Disease Outbreaks
Fungal Phylum Microsporidia
Amebiasis

